P. Kosmidis

437 total citations
37 papers, 367 citations indexed

About

P. Kosmidis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, P. Kosmidis has authored 37 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in P. Kosmidis's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Treatment and Pharmacology (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). P. Kosmidis is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Treatment and Pharmacology (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). P. Kosmidis collaborates with scholars based in Greece, France and United Kingdom. P. Kosmidis's co-authors include George Fountzilas, Νicolas Tsavaris, Dimosthenis Skarlos, Faye Antoniou, Dimitrios Pectasides, Dimitrios Bafaloukos, A. Athanassiou, A. Karabelis, L. Gogou and Meletios Α. Dimopoulos and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

P. Kosmidis

35 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Kosmidis Greece 10 204 172 95 72 44 37 367
Aurelio Matamoros United States 11 176 0.9× 166 1.0× 122 1.3× 49 0.7× 87 2.0× 24 379
T. Brümmendorf Germany 9 138 0.7× 85 0.5× 48 0.5× 82 1.1× 41 0.9× 16 283
Glen Blackman United Kingdom 12 169 0.8× 166 1.0× 120 1.3× 55 0.8× 21 0.5× 19 380
Michael Stahl Germany 11 200 1.0× 99 0.6× 58 0.6× 41 0.6× 97 2.2× 18 302
Riikka Huuhtanen Finland 14 249 1.2× 312 1.8× 129 1.4× 100 1.4× 66 1.5× 21 487
Seog-Yun Park South Korea 10 170 0.8× 172 1.0× 72 0.8× 138 1.9× 84 1.9× 22 433
Riley E. Alexander United States 14 168 0.8× 180 1.0× 269 2.8× 142 2.0× 47 1.1× 19 573
Fai Chung United States 11 181 0.9× 82 0.5× 118 1.2× 58 0.8× 32 0.7× 11 353
Marina Kem United States 10 217 1.1× 118 0.7× 63 0.7× 151 2.1× 70 1.6× 18 418
S Natsugoe Japan 9 282 1.4× 126 0.7× 102 1.1× 127 1.8× 37 0.8× 20 474

Countries citing papers authored by P. Kosmidis

Since Specialization
Citations

This map shows the geographic impact of P. Kosmidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kosmidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kosmidis more than expected).

Fields of papers citing papers by P. Kosmidis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Kosmidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kosmidis. The network helps show where P. Kosmidis may publish in the future.

Co-authorship network of co-authors of P. Kosmidis

This figure shows the co-authorship network connecting the top 25 collaborators of P. Kosmidis. A scholar is included among the top collaborators of P. Kosmidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kosmidis. P. Kosmidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mountzios, Giannis, David Planchard, Giulio Metro, et al.. (2022). 158P Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry. Annals of Oncology. 33. S105–S106. 1 indexed citations
3.
Linardou, Helena, G. Kouvatseas, Giannis Mountzios, et al.. (2019). Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. Cancer Genomics & Proteomics. 16(6). 531–541. 11 indexed citations
4.
Tsiambas, Evangelos, Andreas Karameris, Stavros Gourgiotis, et al.. (2007). Simultaneous deregulation of p16 and cyclin D1 genes in pancreatic ductal adenocarcinoma: a combined immunohistochemistry and image analysis study based on tissue microarrays.. PubMed. 12(2). 261–7. 6 indexed citations
5.
Razis, Evangelia, D. Skarlos, Evangelos Briasoulis, et al.. (2005). Treatment of non-small cell lung cancer with gefitinib (???Iressa???, ZD1839): the Greek experience with a compassionate-use program. Anti-Cancer Drugs. 16(2). 191–198. 8 indexed citations
6.
Bennouna, Jaafar, Ee Hong Tan, Mary O’Brien, et al.. (2004). Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. Journal of Clinical Oncology. 22(14_suppl). 7139–7139. 4 indexed citations
7.
Aravantinos, Gerasimos, Dimitrios Bafaloukos, George Fountzilas, et al.. (2003). Phase II study of docetaxel–vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Annals of Oncology. 14(7). 1094–1099. 26 indexed citations
8.
Samelis, G.F., Dimosthenis Skarlos, Dimitrios Bafaloukos, et al.. (2003). The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology. 61(6). 1211–1215. 17 indexed citations
9.
Jassem, Jacek, P. Kosmidis, Rodryg Ramlau, et al.. (2003). Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Annals of Oncology. 14(11). 1634–1639. 34 indexed citations
10.
Gogas, Helen, Evangelos Briassoulis, George Fountzilas, et al.. (2002). Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology. 20(2). 420–425. 25 indexed citations
11.
Nicolaides, C., George Fountzilas, Nicholas Zoumbos, et al.. (1998). Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin’s Lymphoma Prognostic Index. Oncology. 55(5). 405–415. 31 indexed citations
12.
13.
Tsavaris, N., et al.. (1996). 5-Fluorouracil, Epirubicin, and Mitomycin C Versus 5-Fluorouracil, Epirubicin, Mitomycin C, and Leucovorin in Advanced Gastric Carcinoma. American Journal of Clinical Oncology. 19(5). 517–521. 9 indexed citations
14.
Kosmidis, P., et al.. (1996). A Randomized Trial Comparing Adjuvant Fluorouracil, Epirubicin, and Mitomycin with No Treatment in Operable Gastric Cancer. Chemotherapy. 42(3). 220–226. 36 indexed citations
15.
Pectasides, Dimitrios, Faye Antoniou, L. Gogou, et al.. (1996). TPA, TATI, CEA, AFP, β-HCG, PSA, SCC, and CA 19-9 for Monitoring Transitional Cell Carcinoma of the Bladder. American Journal of Clinical Oncology. 19(3). 271–277. 54 indexed citations
16.
Fountzilas, George, Dimosthenis Skarlos, T. Giannakakis, et al.. (1994). Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer. European Journal of Cancer. 30(7). 965–969. 13 indexed citations
17.
Bafaloukos, Dimitrios, et al.. (1993). First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer. European Journal of Cancer. 29(6). 851–853. 4 indexed citations
18.
Tsavaris, Νicolas, et al.. (1992). Continuous 24-Hour Infusion of Folinic Acid Does Not Increase the Response Rate of 5-Fluorouracil but Only the Toxicity. Oncology. 49(2). 154–156. 1 indexed citations
19.
Tsavaris, Νicolas, et al.. (1990). Concomitant Administration of 4-Hydroxypyrazolopyrimidine (Allopurinol) and High-Dose Continuous Infusion 5-Fluorouracil. Oncology. 47(1). 70–74. 5 indexed citations
20.
Tsavaris, Νicolas, et al.. (1988). Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes.. PubMed. 14(5). 405–6. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aurelio Matamoros Breakdown of academic impact, for papers by T. Brümmendorf Breakdown of academic impact, for papers by Glen Blackman Breakdown of academic impact, for papers by Michael Stahl Breakdown of academic impact, for papers by Riikka Huuhtanen Breakdown of academic impact, for papers by Seog-Yun Park Breakdown of academic impact, for papers by Riley E. Alexander Breakdown of academic impact, for papers by Fai Chung Breakdown of academic impact, for papers by Marina Kem Breakdown of academic impact, for papers by S Natsugoe
Rankless by CCL
2026